Novel agents targeting nitric oxide

Current Vascular Pharmacology

Volumn 10, Issue 1, 2012, Pages 61-76

  Kampoli, Anna Maria ^a   Tousoulis, Dimitris ^a   Tentolouris, Costas ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Atherosclerosis; Bioavailability; Endothelium; Nitric oxide; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; ASCORBIC ACID; BRADYKININ; BRADYKININ B2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; FLUINDOSTATIN; FOLIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN SENSITIZING AGENT; N(G),N(G) DIMETHYLARGININE; NICORANDIL; NITRIC OXIDE; NITRIC OXIDE DONOR; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; PROSTACYCLIN; PROTEIN KINASE B; RHO KINASE; TELMISARTAN; TETRAHYDROBIOPTERIN;

AGE DISTRIBUTION; ARTICLE; ATHEROSCLEROSIS; BIOAVAILABILITY; BRACHIAL ARTERY; DRUG EFFECT; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLOW MEDIATED DILATION; FOREARM BLOOD FLOW; HUMAN; NON INVASIVE MEASUREMENT; NONHUMAN; OXIDATIVE STRESS; PHARMACOLOGICAL STIMULATION; POSTMENOPAUSE; PREGNANCY; PROSTAGLANDIN RELEASE; SEX DIFFERENCE; VASCULAR ENDOTHELIUM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ATHEROSCLEROSIS; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NITRIC OXIDE; VASCULAR DISEASES;

EID: 84857137059     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112798829805     Document Type: Article

References (191)

1. Mayer B, Hemmens B. Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem Sci 1997; 22: 477-81.
2. Hemmens B, Mayer B. Enzymology of nitric oxide synthases. Methods Mol Biol 1998; 100: 1-32.
3. Stuehr DJ. Structure-function aspects in the nitric oxide synthases. Annu Rev Pharmacol Toxicol 1997; 37: 339-59.
4. Ayajiki K, Kindermann M, Hecker M, Fleming I, Busse R. Intra-cellular pH and tyrosine phosphorylation but not calcium determine shear stress-induced nitric oxide production in native endothelial cells. Circ Res 1996; 78: 750-8.
5. Sessa WC, Hecker M, Mitchell JA, Vane JR. The metabolism of L-arginine and its significance for the biosynthesis of endotheliumderived relaxing factor: L-glutamine inhibits the generation of Larginine by cultured endothelial cells. Proc Natl Acad Sci USA 1990; 87: 8607-11.
6. Tousoulis D, Antoniades C, Stefanadis C. Nitric oxide in coronary artery disease: effects of antioxidants. Eur J Clin Pharmacol 2006; 62: 101-7.
7. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113: 1708-14.
8. Napoli C, de Nigris F, Williams-Ignarro S, Pignalosa O, Sica V, Ignarro LJ. Nitric oxide and atherosclerosis: an update. Nitric Oxide 2006; 15: 265-79.
9. Verbeuren TJ, Coene MC, Jordaens FH, Van Hove CE, Zonnekeyn LL, Herman AG. EVect of hypercholesterolemia on vascular reactivity in the rabbit. II. InXuence of treatment with dipyridamole on endothelium-dependent and endothelium-independent responses in isolated aortas of control and hypercholesterolemic rabbits. Circ Res 1986; 59: 496-504.
10. Dusting GJ, Macdonald PS. Endogenous nitric oxide in cardiovascular disease and transplantation. Ann Med 1995; 27: 395-406.
11. Meredith IT, Anderson TJ, Uehata A, Yeung AC, Selwyn AP, Ganz P. Role of endothelium in ischemic coronary syndromes. Am J Cardiol 1993; 72: 27C-31C.
12. Nakayama M, Yasue H, Yoshimura M, et al. T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999; 99: 2864-70.
13. Cattaruzza M, Guzik TJ, Sodowski W, et al. Shear stress insensitivity of endothelial nitric oxide synthase expression as a genetic risk factor for coronary heart disease. Circ Res 2004; 95: 841-7.
14. Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol 2004; 61: 1652-61.
15. Hingorani AD. Endothelial nitric oxide synthase polymorphisms and hypertension. Curr Hypertens Rep 2003; 5: 19-25.
16. Persu A, Stoenoiu MS, Messiaen T, et al. Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 2002; 11: 229-41.
17. McDonald DM, Alp NJ, Channon KM. Functional comparison of the endothelial nitric oxide synthase Glu298Asp polymorphic variants in human endothelial cells. Pharmacogenetics 2004; 14: 831-9.
18. Guzik TJ, Black E, West NE, et al. Relationship between the G894T polymorphism (Glu298Asp variant) in endothelial nitric oxide synthase and nitric oxide-mediated endothelial function in human atherosclerosis. Am J Med Genet 2001; 100: 130-7.
19. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004; 24: 1023-30.
20. Jones LC, Tran CT, Leiper JM, Hingorani AD, Vallance P. Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun 2003; 310: 836-43.
21. Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 413-20.
22. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
23. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6: 508-19.
24. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
25. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008; 8: 802-15.
26. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2: 907-16.
27. Oswald IP, Wynn TA, Sher A, James SL. NO as an effector molecule of parasite killing: modulation of its synthesis by cytokines. Comp Biochem Physiol Pharmacol Toxicol Endocrinol 1994; 108: 11-8.
28. Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS, Tannenbaum SR. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci USA 1992; 89: 3030-4.
29. Li CQ, Pang B, Kiziltepe T, et al. Threshold effects of nitric oxideinduced toxicity and cellular responses in wild-type and p53-null human lymphoblastoid cells. Chem Res Toxicol 2006; 19: 399-406.
30. Hibbs JB, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988; 157: 87-94.
31. Zweier JL, Talukder MA. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res 2006; 70: 181-90.
32. Stellos K, Langer H, Daub K, et al. Platelet-derived stromal cell-derived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells. Circulation 2008; 117: 206-15.
33. Tarzami ST, Wang G, Li W, Green L, Singh JP. Thrombin and PAR-1 stimulate differentiation of bone marrow-derived endothelial progenitor cells. J Thromb Haemost 2006; 4: 656-63.
34. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 2005; 45: 526-9.
35. Chen JZ, Zhang FR, Tao QM, et al. Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia. Clin Sci (Lond.) 2004; 107: 273-80.
36. Chen YH, Lin SJ, Lin FY, et al. High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes 2007; 56: 1559-68.
37. Laufs U, Wassmann S, Czech T, et al. Physical inactivity increases oxidative stress, endothelial dysfunction, and atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25: 809-14.
38. Hamed S, Brenner B,Roguin A. Nitric oxide: a key factor behind the dysfunctionality of endothelial progenitor cells in diabetes mellitus type-2. Cardiovasc Res 2011; 91: 9-15.
39. Tousoulis D, Antoniades C, Stefanadis C. Evaluating endothelial function in humans: a guide to invasive and non-invasive techniques. Heart 2005; 91: 553-8.
40. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653-8.
41. Chan L, Shaw AG, Busfield F, et al. Carotid artery intimal medial thickness, brachial artery flow-mediated vasodilation and cardiovascular risk factors in diabetic and non-diabetic indigenous Australians. Atherosclerosis 2005; 180: 319-26.
42. Frick M, Suessenbacher A, Alber HF, et al. Prognostic value of brachial artery endothelial function and wall thickness. J Am Coll Cardiol 2005; 46: 1006-10.
43. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003; 108: 17, 2093-8.
44. Tentolouris C, Tousoulis D, Antoniades C, et al. Endothelial function and proinflammatory cytokines in patients with ischemic heart disease and dilated cardiomyopathy. Int J Cardiol 2004; 94: 301-5.
45. Tousoulis D, Charakida M, Stefanadis C. Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure. Int J Cardiol 2005; 100; 347-53.
46. Meyer B, Mortl D, Strecker K, et al. Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide. J Am Coll Cardiol 2005; 46: 1011-8.
47. Chan SY, Mancini GB, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol 2003; 42: 1037-43.
48. Shimbo D, Grahame-Clarke C, Miyake Y, et al. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis 2006; 192: 197-203.
49. Hashimoto M, Akishita M, Eto M, et al. Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 1995; 92: 3431-5.
50. Dørup I, Skajaa K, Sørensen KE. Normal pregnancy is associated with enhanced endothelium-dependent flow-mediated vasodilation. Am J Physiol 1999; 276: H821-5.
51. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol. 1994; 24: 471-6.
52. Kalantaridou SN, Naka KK, Bechlioulis A, Makrigiannakis A, Michalis L, Chrousos GP. Premature ovarian failure, endothelial dysfunction and estrogen-progestogen replacement. Trends Endocrinol Metab 2006; 17: 101-9.
53. Gilligan DM, Quyyumi AA, Cannon III, RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994; 89: 2545-51.
54. Roqué M, Heras M, Roig E, et al. Short-term effects of transdermal estrogen replacement therapy on coronary vascular reactivity in postmenopausal women with angina pectoris and normal results on coronary angiograms. J Am Coll Cardiol 1998; 31: 139-43.
55. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994; 121: 936-41.
56. Ho JYP, Chen MJ, Sheu WHH, et al. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Hum Reprod 2006; 21: 2715-20.
57. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon III RO. Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol 1995; 75: 264-8.
58. Koh KK, Cardillo C, Bui MN, et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999; 99: 354-60.
59. Koh KK, Kang MH, Jin DK, et al. Vascular effects of estrogen in type II diabetic postmenopausal women. J Am Coll Cardiol 2001; 38: 1409-15.
60. Koh KK, Jin DK, Yang SH, et al. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 2001; 103: 1961-6.
61. Vitale C, Fini M, Leonardo F, et al. Effect of estradiol alone or in combination with cyproterone acetate upon vascular function of postmenopausal women at increased risk for cardiovascular disease. Maturitas 2001; 40: 239-45.
62. Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 2004; 24: 571-6.
63. Sherwood A, Bower JK, McFetridge-Durdle J, Blumenthal JA, Newby LK, Hinderliter AL. Age modulates the short-term effects of transdermal 17 -estradiol on endothelium-dependent vascular function in postmenopausal women. Arterioscler Thromb Vasc Biol 2007; 27: 1782-7.
64. Vitale C, Mercuro G, Cerquetani E, et al. Time since menopause influences the acute and chronic effect of estrogens on endothelial function. Arterioscler Thromb Vasc Biol 2008; 28: 348-52.
65. Xing D, Nozell S, Chen YF, Hage F, Oparil S. Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol 2009; 29: 289-95.
66. Kalantaridou SN, Naka KK, Kalantaridou E, et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab 2004; 89: 3907-13.
67. Koh KK. Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovasc Res 2002; 55: 714-26.
68. Chambliss KL, Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 2002; 23: 665-86.
69. Newman WP, III, Freedman DS, Voors AW, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study N Engl J Med. 1986; 314: 138-44.
70. Jarvisalo MJ, Harmoinen A, Hakanen M, et al. Elevated serum C-reactive protein levels and early arterial changes in healthy children. Arterioscler Thromb Vasc Biol 2002; 22: 1323-8.
71. Prasad A, Zhu J, Halcox JP, Waclawiw MA, Epstein SE, Quyyumi AA. Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation 2002; 106: 184-90.
72. Charakida M, Donald AE, Green H, et al. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation 2005; 112: 103-9.
73. Bonnet D, Aggoun Y, Szezepanski I, Bellal N, Blanche S. Arterial stiffness and endothelial dysfunction in HIV-infected children. AIDS 2004; 18: 1037-41.
74. Khan F. Assessment of endothelial function as a marker of cardio-vascular risk in patients with rheumatoid arthritis. Int J Rheum Dis 2010; 13: 189-95.
75. Deng YB, Xiang HJ, Chang Q, Li CL. Evaluation by high-resolution ultrasonography of endothelial function in brachial artery after Kawasaki disease and the effects of intravenous administration of vitamin C. Circ J 2002; 66: 908-12.
76. Celermajer DS, Sorensen K, Ryalls M, et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 1993; 22: 854-8.
77. Bennett-Richards K, Kattenhorn M, Donald A, et al. Does oral folic acid lower total homocysteine levels and improve endothelial function in children with chronic renal failure? Circulation 2002; 105: 1810-5.
78. Bennett-Richards KJ, Kattenhorn M, Donald AE, et al. Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure. Kidney Int 2002; 62: 1372-8.
79. Kari JA, Donald AE, Vallance DT, et al. Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int 1997; 52: 468-72.
80. Clarkson P, Celermajer DS, Powe AJ, Donald AE, Henry RM, Deanfield JE. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation 1997; 96: 3378-83.
81. de Jongh S, Lilien MR, Bakker HD, Hutten BA, Kastelein JJ, Stroes ES. Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia. Atherosclerosis 2002; 163: 193-7.
82. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004-10.
83. Sun W, Lee TS, Zhu M, et al. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 2006; 114: 2655-62.
84. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273: 24266-71.
85. Yaktubay Döndaş N, Sucu N, Coşkun Yilmaz B, et al. Molecular mechanism of vasorelaxant and antiatherogenic effects of the statins in the human saphenous vein graft. Eur J Pharmacol 2011; 666: 150-7.
86. Ghaffari N, Ball C, Kennedy JA, Stafford I, Beltrame JF. Acute modulation of vasoconstrictor responses by pravastatin in small vessels. Circ J 2011;75: 1506-14.
87. Mangialardi G, Monopoli A, Ongini E, et al. Nitric oxide-donating statin improves multiple functions of circulating angiogenic cells. Br J Pharmacol 2011; 164: 570-83.
88. Tousoulis D, Papageorgiou N, Briasoulis A, et al. Conflicting effects of nitric oxide and oxidative stress in chronic heart failure: potential therapeutic strategies. Heart Fail Rev 2011 Feb 4 [Epub ahead of print].
89. Skogastierna C, Luksha L, Kublickiene K, Eliasson E, Rane A, Ekström L. Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide. Heart Vessels 2011 Jan 7 [Epub ahead of print].
90. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A metaregression analysis. J Am Coll Cardiol 2005; 46: 1855-62.
91. Briel M, Schwartz GG, Thompson PL, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006; 295: 2046-56.
92. Chang SM, Yazbek N, Lakkis NM. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv 2004; 62: 193-7.
93. Tsuda K. Statins and nitric oxide production against ischemic stroke. Stroke 2008; 39: e170.
94. Faggiotto A, Paoletti R. State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. Hypertension 1999; 34: 987-96.
95. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94: 258-65.
96. Virdis A, Ghiadoni L, Taddei S. Effects of antihypertensive treatment on endothelial function. Curr Hypertens Rep 2011; 13: 276-81.
97. Fouad AA, Qureshi HA, Al-Sultan AI, Yacoubi MT, Al-Melhim WN. Nephroprotective effect of telmisartan in rats with ischemia/reperfusion renal injury. Pharmacology 2010; 85: 158-67.
98. Gemici B, Tan R, Ongüt G, Izgüt-Uysal VN. Expressions of inducible nitric oxide synthase and cyclooxygenase-2 in gastric ischemia-reperfusion: role of angiotensin II. J Surg Res 2010; 161: 126-33.
99. Cousin M, Custaud MA, Baron-Menguy C, et al. Role of angiotensin II in the remodeling induced by a chronic increase in flow in rat mesenteric resistance arteries. Hypertension 2010; 55: 109-15.
100. Ritt M, Ott C, Raff U, et al. Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus. Am J Kidney Dis 2009; 53: 281-9.
101. Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM. Impact of telmisartan vs. ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007; 30: 1351-6.
102. O'Driscoll G, Green D, Maiorana A, Stanton K, Colreavy F, Taylor R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1999; 33: 1506-11.
103. Morawietz H, Rohrbach S, Rueckschloss U, et al. Increased cardiac endothelial nitric oxide synthase expression in patients taking angiotensin-converting enzyme inhibitor therapy. Eur J Clin Invest 2006; 36: 705-12.
104. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-10.
105. Jackson SM, Parhami F, Xi XP, et al. Peroxisome proliferatoractivated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 1999; 19: 2094-104.
106. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferatoractivated receptor-gamma activators. Circulation 2000; 101: 235-8.
107. Giaginis C, Tsourouflis G, Theocharis S. Peroxisome proliferatoractivated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury. Curr Mol Med 2008; 8: 562-79.
108. Caballero AE, Saouaf R, Lim SC, et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 2003; 52: 173-80.
109. Watanabe Y, Sunayama S, Shimada K, et al. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thromb 2000; 7: 159-63.
110. Vinik A, Parson H, Ullal J. The role of PPARs in the microvascular dysfunction in diabetes. Vascul Pharmacol 2006; 45: 54-64.
111. Hidaka T, Nakagawa K, Goto C, et al. Pioglitazone improves endothelium-dependent vasodilation in hypertensive patients with impaired glucose tolerance in part through a decrease in oxidative stress. Atherosclerosis 2010; 210: 521-4.
112. Morsy MA, Ashour OM, Fouad AA, Abdel-Gaber SA. Gastroprotective effects of the insulin sensitizers rosiglitazone and metformin against indomethacin-induced gastric ulcers in Type 2 diabetic rats. Clin Exp Pharmacol Physiol 2010; 37: 173-7.
113. Yasuda S, Kobayashi H, Iwasa M, et al. Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction. Am J Physiol Heart Circ Physiol 2009; 296: H1558-65.
114. Huang PH, Sata M, Nishimatsu H, Sumi M, Hirata Y, Nagai R. Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice. Biomed Pharmacother 2008; 62: 46-52.
115. Fujishima S, Ohya Y, Nakamura Y, Onaka U, Abe I, Fujishima M. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans. Am J Hypertens 1998; 11: 1134-7.
116. Tack CJ, Ong MK, Lutterman JA, Smits P. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone. Diabetologia 1998; 41: 569-76.
117. Kaur B, Singh N, Jaggi AS. Exploring mechanism of pioglitazoneinduced memory restorative effect in experimental dementia. Fundam Clin Pharmacol 2009; 23: 557-66.
118. Tousoulis D, Antoniades C, Tentolouris C, Goumas G, Stefanadis C, Toutouzas P. L-arginine in cardiovascular disease: dream or reality? Vasc Med 2002; 7: 203-11.
119. Tentolouris C, Tousoulis D, Goumas G, Stefanadis C, Davies G, Toutouzas P. L-Arginine in coronary atherosclerosis. Int J Cardiol 2000; 75: 123-8.
120. Jialal I, Devaraj S. Antioxidants and atherosclerosis: don't throw out the baby with the bath water. Circulation 2003; 107: 926-8.
121. Vukosavljevic N, Jaron D, Barbee KA, and Buerk DG. Quantifying the L-arginine paradox in vivo. Microvasc Res 2006; 71: 48-54.
122. Goumas G, Tentolouris C, Tousoulis D, Stefanadis C, Toutouzas P. Therapeutic modification of the L-arginine-eNOS pathway in cardiovascular diseases. Atherosclerosis 2003; 154: 255-67.
123. Boger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the l-arginine paradox and acts as a novel cardiovascular risk factor. J Nutr 2004; 134: 2842-7.
124. Channon KM, Guzik TJ. Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. J Physiol Pharmacol 2002; 53: 515-24.
125. Calver A, Collier J, Leone A, Moncada S, Vallance P. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens 1993; 7: 193-4.
126. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455-9.
127. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-8.
128. Ari H, Ari S, Erdogan E, et al. A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine. Heart Vessels 2010; 25: 19-26.
129. Cavusoglu E, Ruwende C, Chopra V, et al. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. Atherosclerosis 2010; 210: 226-31.
130. Surdacki A, Marewicz E, Wieczorek-Surdacka E, et al. Synergistic effects of asymmetrical dimethyl-L-arginine accumulation and endothelial progenitor cell deficiency on renal function decline during a 2-year follow-up instable angina. Nephrol Dial Transplant 2010; 25: 2576-83.
131. Fleissner F, Jazbutyte V, Fiedler J, et al. Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. Circ Res 2010; 107: 138-43.
132. Boger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006; 38: 126-36.
133. Lucotti P, Monti L, Setola E,et al. Oral L-arginine supplementation improves endothelial function and ameliorates insulin sensitivity and inflammation in cardiopathic non-diabetic patients after an aortocoronary bypass. Metabolism 2009; 58: 1270-6.
134. Settergren M, Böhm F, Malmström RE, Channon KM, Pernow J. L-arginine and tetrahydrobiopterin protects against ischemia/ reperfusion-induced endothelial dysfunction in patients with type 2 diabetes mellitus and coronary artery disease. Atherosclerosis 2009; 204: 73-8.
135. Okonski P, Banach M, Rysz J, et al. L-arginine improves hemodynamic function and coronary flow in an experimental model of ischemia-reperfusion injury. Ann Transplant 2006; 11: 28-34.
136. The-HPS-Study-Investigators. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
137. Loscalzo J. Adverse effects of supplemental L-arginine in atherosclerosis: consequences of methylation stress in a complex catabolism? Arterioscler Thromb Vasc Biol 2003; 23: 3-5.
138. Oomen CM, van Erk MJ, Feskens EJ, Kok FJ, Kromhout D. Arginine intake and risk of coronary heart disease mortality in elderly men. Arterioscler Thromb Vasc Biol 2000; 20: 2134-9.
139. Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 413-20.
140. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 2003; 278: 22546-54.
141. Masano T, Kawashima S, Toh R, et al. Beneficial effects of exogenous tetrahydrobiopterin on left ventricular remodeling after myocardial infarction in rats: the possible role of oxidative stress caused by uncoupled endothelial nitric oxide synthase. Circ J 2008; 72: 1512-9.
142. Schmidt TS, McNeill E, Douglas G, et al. Tetrahydrobiopterin supplementation reduces atherosclerosis and vascular inflammation in apolipoprotein E-knockout mice. Clin Sci (Lond) 2010; 119: 131-42.
143. Szabó G, Seres L, Soós P, et al. Tetrahydrobiopterin improves cardiac and pulmonary function after cardiopulmonary bypass. Eur J Cardiothorac Surg 2011; 40: 695-700.
144. Heitzer T, Brockhoff C, Mayer B, et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ Res 2000; 86: E36-41.
145. Nystrom T, Nygren A, Sjoholm A. Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease. Am J Physiol Endocrinol Metab 2004; 287: E919-25.
146. Fukuda Y, Teragawa H, Matsuda K, Yamagata T, Matsuura H, Chayama K. Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia. Heart 2002; 87: 264-9.
147. Berbée M, Fu Q, Kumar KS, Hauer-Jensen M. Novel strategies to ameliorate radiation injury: a possible role for tetrahydrobiopterin. Curr Drug Targets 2010; 11: 1366-74.
148. Gangula PR, Mukhopadhyay S, Ravella K, et al. Tetrahydrobiopterin (BH4), a cofactor for nNOS, restores gastric emptying and nNOS expression in female diabetic rats. Am J Physiol Gastrointest Liver Physiol 2010; 298: G692-9.
149. Sucher R, Gehwolf P, Oberhuber R, et al. Tetrahydrobiopterin protects the kidney from ischemia-reperfusion injury. Kidney Int 2010; 77: 681-9.
150. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325: 1202.
151. Bunout D, Petermann M, Hirsch S, et al. Low serum folate but normal homocysteine levels in patients with atherosclerotic vascular disease and matched healthy controls. Nutrition. 2000; 16: 434-8.
152. Verhaar MC, Wever RM, Kastelein JJ, et al. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial. Circulation 1999; 100: 335-8.
153. Doshi SN, McDowell IF, Moat SJ, et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 2002; 105: 22-6.
154. Hyndman ME, Verma S, Rosenfeld RJ, Anderson TJ, Parsons HG. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol 2002; 282: H2167-72.
155. Cheng Z, Jiang X, Kruger WD, et al. Hyperhomocysteinemia impairs endothelium-derived hyperpolarizing factor-mediated vasorelaxation in transgenic cystathionine beta-synthase-deficient mice. Blood 2011; 118: 1998-2006.
156. Yan TT, Li Q, Zhang XH, et al. Homocysteine impaired endothelial function through compromised vascular endothelial growth factor/ Akt/endothelial nitric oxide synthase signaling. Clin Exp Pharmacol Physiol 2010; 37: 1071-7.
157. Jia F, Wu C, Chen Z, Lu G. AMP-activated protein kinase inhibits homocysteine-induced dysfunction and apoptosis in endothelial progenitor cells. Cardiovasc Drugs Ther 2011; 25: 21-9.
158. Qipshidze N, Metreveli N, Lominadze D, Tyagi SC. Folic acid improves acetylcholine-induced vasoconstriction of coronary vessels isolated from hyperhomocysteinemic mice: An implication to coronary vasospasm. J Cell Physiol 2010; 226: 2712-20.
159. Vermeulen EG, Stehouwer CD, Twisk JW, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebocontrolled trial. Lancet 2000; 355: 517-22.
160. Spijkerman AM, Smulders YM, Kostense PJ, et al. Stehouwer. Sadenosylmethionine and 5-methyltetrahydrofolate are associated with endothelial function after controlling for confounding by homocysteine: the Hoorn Study. Arterioscler Thromb Vasc Biol 2005; 25: 778-84.
161. Antoniades C, Shirodaria C, Leeson P, et al. 5-methyltetrahydrofolate rapidly improves endothelial function and superoxide production in human atherosclerosis: Effects on tetrahydrobiopterin-dependent eNOS coupling. J Am Coll Cardiol 2006; 47: 356.
162. Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998; 97: 237-41.
163. Doshi SN, McDowell IF, Moat SJ, et al. Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol 2001; 21: 1196-202.
164. Stroes ES, van Faassen EE, Yo M, Martasek P, Boer P, Govers R, Rabelink TJ. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000; 86: 1129-34.
165. Toutouzas PC, Tousoulis D, Davies GJ. Nitric oxide synthesis in atherosclerosis. Eur Heart J 1998; 19: 1504-11.
166. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 91: 2546-51.
167. Antoniades C, Tousoulis D, Vasiliadou C, et al. Combined effects of smoking and hypercholesterolemia on inflammatory process, thrombosis/fibrinolysis system, and forearm hyperemic response. Am J Cardiol 2004; 94: 1181-4.
168. Antoniades C, Tousoulis D, Tountas C, et al. Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis: the effects of vitamin C. Diabet Med 2004; 21: 552-8.
169. Antoniades C, Tousoulis D, Tentolouris C, et al. Effects of antioxidant vitamins C and E on endothelial function and thrombosis/ fibrinolysis system in smokers. Thromb Haemost 2003; 89: 990-5.
170. Arellano-Mendoza MG, Vargas-Robles H, Del Valle-Mondragon L, Rios A, Escalante B. Prevention of renal injury and endothelial dysfunction by chronic L-arginine and antioxidant treatment. Ren Fail 2011; 33: 47-53.
171. Crecelius AR, Kirby BS, Voyles WF, Dinenno FA. Nitric oxide, but not vasodilating prostaglandins, contributes to the improvement of exercise hyperemia via ascorbic acid in healthy older adults. Am J Physiol Heart Circ Physiol 2010; 299: H1633-41.
172. Muharis SP, Top AG, Murugan D, Mustafa MR. Palm oil tocotrienol fractions restore endothelium dependent relaxation in aortic rings of streptozotocin-induced diabetic and spontaneously hypertensive rats. Nutr Res 2010; 30: 209-16.
173. Franco Mdo C, Ponzio BF, Gomes GN, et al. Micronutrient prenatal supplementation prevents the development of hypertension and vascular endothelial damage induced by intrauterine malnutrition. Life Sci 2009; 85: 327-33.
174. The-HPS-Study-Investigators. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
175. Herman AG, Moncada S. Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis. Eur Heart J 2005; 26: 1945-55.
176. The-IONA-Investigators. Impact of nicorandil in angina: subgroup analyses. Heart 2004; 90: 1427-30.
177. The-IONA-Investigators. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359: 1269-75.
178. Sakamoto T, Kaikita K, Miyamoto S, et al. Effects of nicorandil on endogenous fibrinolytic capacity in patients with coronary artery disease. Circ J 2004; 68: 232-5.
179. Trakranrungsie N, Will JA. Comparative vasodilation of peroxynitrite and 3-morpholinosydnonimine. Life Sci 2001; 69: 2349-59.
180. Belhassen L, Carville C, Pelle G, et al. Molsidomine improves flow-dependent vasodilation in brachial arteries of patients with coronary artery disease. J Cardiovasc Pharmacol 2000; 35: 560-3.
181. Takahashi M, Ikeda U, Masuyama J, Funayama H, Kano S, Shimada K. Nitric oxide attenuates adhesion molecule expression in human endothelial cells. Cytokine 1996; 8: 817-21.
182. Van Hove C, Carreer-Bruhwyler F, Geczy J Herman AG. Longterm treatment with the NO-donor molsidomine reduces circulating ICAM-1 levels in patients with stable angina. Atherosclerosis 2005; 180: 399-405.
183. Wallace JL, Ignarro LJ, Fiorucci S. Potential cardioprotective actions of no-releasing aspirin. Nat Rev Drug Discov 2002; 1: 375-82.
184. Grosser N, Schroder H. A common pathway for nitric oxide release from NO-aspirin and glyceryl trinitrate. Biochem Biophys Res Commun 2000; 274: 255-8.
185. Carini M, Aldini G, Stefani R, Orioli M, Facino RM. Nitrosylhemoglobin, an unequivocal index of nitric oxide release from nitroaspirin: in vitro and in vivo studies in the rat by ESR spectroscopy. J Pharm Biomed Anal 2001; 26: 509-18.
186. Bolla M, Momi S, Gresele P, Del Soldato P. Nitric oxide-donating aspirin (NCX 4016): an overview of its pharmacological properties and clinical perspectives. Eur J Clin Pharmacol 2006; 62: 145-54.
187. Fiorucci S, Mencarelli A, Mannucci R, et al. NCX-4016, a nitric oxide-releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial function. Faseb J 2002; 16: 1645-7.
188. Muzaffar S, Shukla N, Angelini G, Jeremy JY. Nitroaspirins and morpholinosydnonimine but not aspirin inhibit the formation of superoxide and the expression of gp91phox induced by endotoxin and cytokines in pig pulmonary artery vascular smooth muscle cells and endothelial cells. Circulation 2004; 110: 1140-7.
189. Napoli C, Aldini G, Wallace JL, et al. Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. Proc Natl Acad Sci USA 2002; 99: 1689-94.
190. Muscara MN, Lovren F, McKnight W, et al. Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. Br J Pharmacol 2001; 133: 1314-22.
191. Fiorucci S, Mencarelli A, Meneguzzi A, et al. Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. J Am Coll Cardiol 2004; 44: 635-41.